A surface modified electrode and a method of preparing the surface modified electrode are provided. The surface modified electrode includes a glassy carbon electrode and a coating of a compound of formula I disposed on the glassy carbon electrode. The present disclosure also relates to a method of preparing the surface modified electrode. The method includes depositing a slurry of the compound of Formula I on the glassy carbon electrode to form a film and coating a polymer matrix on the film to obtain the surface modified electrode. The present disclosure also relates to a method of preparing the compound of Formula I. The method includes condensing 4-bromobenzaldehyde (4-BBD) and 4-methyl-benzenesulphonylhydrazine (4-MBSH), to obtain a first mixture and precipitating the first mixture to obtain the compound of Formula I. The surface modified electrode is used in an electrochemical sensor for the detection of metal ions. ##STR00001##

A surface modified electrode and a method of preparing the surface modified electrode are provided. The surface modified electrode includes a glassy carbon electrode and a coating of a compound of formula I disposed on the glassy carbon electrode. The present disclosure also relates to a method of preparing the surface modified electrode. The method includes depositing a slurry of the compound of Formula I on the glassy carbon electrode to form a film and coating a polymer matrix on the film to obtain the surface modified electrode. The present disclosure also relates to a method of preparing the compound of Formula I. The method includes condensing 4-bromobenzaldehyde (4-BBD) and 4-methyl-benzenesulphonylhydrazine (4-MBSH), to obtain a first mixture and precipitating the first mixture to obtain the compound of Formula I. The surface modified electrode is used in an electrochemical sensor for the detection of metal ions. ##STR00001##

The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:

##STR00001##

wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently —CR.sub.2═ or —N═, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, —S(═O).sub.2—NH—R.sub.8, R.sub.8 is, for example, a C1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

This invention relates to a method for producing a high-purity cyclohexenone long-chain alcohol represented by formula I, and produces the compound of formula I by a metal-mediated Barbier reaction. The method of the present invention has advantages in its short scheme, high yield, and high-purity product, and is suitable for industrial scale up. ##STR00001##

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.